TNSN04102A1 - Association d'un inhibiteur de pde4 selectif, et d'un agoniste de recepteur beta-2 adrenergique - Google Patents

Association d'un inhibiteur de pde4 selectif, et d'un agoniste de recepteur beta-2 adrenergique

Info

Publication number
TNSN04102A1
TNSN04102A1 TNP2004000102A TNSN04102A TNSN04102A1 TN SN04102 A1 TNSN04102 A1 TN SN04102A1 TN P2004000102 A TNP2004000102 A TN P2004000102A TN SN04102 A TNSN04102 A TN SN04102A TN SN04102 A1 TNSN04102 A1 TN SN04102A1
Authority
TN
Tunisia
Prior art keywords
association
receptor agonist
adrenergic receptor
pde4 inhibitor
beta
Prior art date
Application number
TNP2004000102A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN04102A1 publication Critical patent/TNSN04102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE UNE ASSOCIATION D'UN INHIBITEUR DE PDE4 SELECTIF; TEL QUE DEFINI DANS LE PRESENT MEMOIRE; ET D'UN AGONISTE DE RECEPTEUR β2 ADRENERGIQUE POUR UNE ADMINISTRATION SIMULTANEE; SEQUENTIELLE OU SEPAREE PAR INHALATION DANS LE TRAITEMENT D'UNE MALADIE OBSTRUCTIVE DES VOIES AERIENNES OU D'UNE AUTRE MALADIE INFLAMMATOIRE.
TNP2004000102A 2001-12-07 2004-06-04 Association d'un inhibiteur de pde4 selectif, et d'un agoniste de recepteur beta-2 adrenergique TNSN04102A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129395.0A GB0129395D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
PCT/IB2002/004922 WO2003047578A1 (fr) 2001-12-07 2002-11-22 Combinaison d'un inhibiteur selectif de pde4 et d'un agoniste des recepteurs beta-2 adrenergiques

Publications (1)

Publication Number Publication Date
TNSN04102A1 true TNSN04102A1 (fr) 2006-06-01

Family

ID=9927247

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000102A TNSN04102A1 (fr) 2001-12-07 2004-06-04 Association d'un inhibiteur de pde4 selectif, et d'un agoniste de recepteur beta-2 adrenergique

Country Status (33)

Country Link
US (2) US20030119862A1 (fr)
EP (1) EP1455783A1 (fr)
JP (1) JP2005511657A (fr)
KR (1) KR20050044699A (fr)
CN (1) CN1599609A (fr)
AP (1) AP2004003054A0 (fr)
AR (1) AR037712A1 (fr)
AU (1) AU2002353255A1 (fr)
BR (1) BR0214776A (fr)
CA (1) CA2468676A1 (fr)
CO (1) CO5590899A2 (fr)
EA (1) EA200400640A1 (fr)
EC (1) ECSP045142A (fr)
GB (1) GB0129395D0 (fr)
HN (1) HN2002000356A (fr)
HR (1) HRP20040515A2 (fr)
HU (1) HUP0402546A3 (fr)
IL (1) IL162098A0 (fr)
IS (1) IS7277A (fr)
MA (1) MA27152A1 (fr)
MX (1) MXPA04004930A (fr)
NO (1) NO20042870L (fr)
NZ (1) NZ533030A (fr)
OA (1) OA12736A (fr)
PA (1) PA8560601A1 (fr)
PE (1) PE20031066A1 (fr)
PL (1) PL370770A1 (fr)
SV (1) SV2004001430A (fr)
TN (1) TNSN04102A1 (fr)
TW (1) TWI242433B (fr)
UY (1) UY27564A1 (fr)
WO (1) WO2003047578A1 (fr)
ZA (1) ZA200403905B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
WO2012098495A1 (fr) * 2011-01-19 2012-07-26 Glenmark Pharmaceuticals Sa Composition pharmaceutique qui comprend le revamilast et un agoniste de bêta-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0837860T3 (da) * 1995-06-06 2002-05-27 Pfizer Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
KR100701904B1 (ko) * 1999-08-21 2007-04-02 알타나 파마 아게 Ｐｄｅ 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합

Also Published As

Publication number Publication date
SV2004001430A (es) 2004-02-24
OA12736A (en) 2006-06-29
GB0129395D0 (en) 2002-01-30
HRP20040515A2 (en) 2004-10-31
ZA200403905B (en) 2005-06-22
IL162098A0 (en) 2005-11-20
CO5590899A2 (es) 2005-12-30
HN2002000356A (es) 2003-02-21
WO2003047578A1 (fr) 2003-06-12
TWI242433B (en) 2005-11-01
CN1599609A (zh) 2005-03-23
AR037712A1 (es) 2004-12-01
EA200400640A1 (ru) 2004-12-30
EP1455783A1 (fr) 2004-09-15
CA2468676A1 (fr) 2003-06-12
NZ533030A (en) 2007-03-30
UY27564A1 (es) 2003-07-31
PA8560601A1 (es) 2005-02-04
AU2002353255A1 (en) 2003-06-17
HUP0402546A2 (hu) 2005-04-28
US20040167153A1 (en) 2004-08-26
KR20050044699A (ko) 2005-05-12
ECSP045142A (es) 2004-07-23
PL370770A1 (en) 2005-05-30
MA27152A1 (fr) 2005-01-03
BR0214776A (pt) 2004-11-09
JP2005511657A (ja) 2005-04-28
TW200300678A (en) 2003-06-16
AP2004003054A0 (en) 2004-06-30
IS7277A (is) 2004-05-21
HUP0402546A3 (en) 2008-04-28
PE20031066A1 (es) 2003-12-24
US20030119862A1 (en) 2003-06-26
MXPA04004930A (es) 2005-04-08
NO20042870L (no) 2004-07-06

Similar Documents

Publication Publication Date Title
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005084655A8 (fr) Derives de 1-aminocyclohexane pour le traitement de l'agitation et d'autres troubles du comportement, en particulier ceux qui sont associes a la maladie d'alzheimer
MXPA03008955A (es) Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP2275959A3 (fr) Procédé de criblage d'un agent thérapeutique pour la détermination de l'efficacité thérapeutique
BRPI0410296A (pt) sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma
WO2004071431A3 (fr) Composition et methode de traitement de troubles neurodegeneratifs
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
CA2391808A1 (fr) Procede de traitement de symptomes de troubles du systeme nerveux central
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
MA30901B1 (fr) Therapie de combinaison sequentielle
MA27591A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
TNSN04102A1 (fr) Association d'un inhibiteur de pde4 selectif, et d'un agoniste de recepteur beta-2 adrenergique
TNSN04101A1 (fr) ASSOCIATIONS PHARMACEUTIQUES D'UN AGONISTE DE RECEPTEUR D'ADENOSINE A2a ET D'UN AGONISTE DE RECEPTEUR ADRENERGIQUE B2
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
SI1553985T1 (sl) Bifenili kot sredstva za slikanje pri Alzheimerjevi bolezni
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung